Ticagrelor
Ticagrelor is an active ingredient of the class «antithrombotic».
Coronary medication
Boxed warning (US label)
Bleeding risk. BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause significant, sometimes fatal bleeding. • Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage •. • Do not start BRILINTA in patients…
What it is used for
- Acute myocardial infarction
- Heart disease
- Unstable angina
- Acute coronary syndrome
- Myocardial infarction
- Thrombosis
- Stroke
- Coronary artery disease
- Type 2 diabetes
- Peripheral vascular disease
BRILINTA is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel.
Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (ACS) or a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event…
How it works
- Purinergic receptor P2Y12 negative allosteric modulator
Class: antithrombotic
Common side effects
The following adverse reactions are also discussed elsewhere in the labeling: • Bleeding • Dyspnea Most common adverse reactions (>5%) are bleeding and dyspnea.
Who should not take it
History of intracranial hemorrhage. • Active pathological bleeding. • Hypersensitivity to ticagrelor or any component of the product. 4.1 History of Intracranial Hemorrhage BRILINTA is contraindicated in patients with a history of intracranial hemorrhage…
Pregnancy and breastfeeding
Available data from case reports with BRILINTA use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Interactions
- Alteplase — retroperitoneal hemorrhage
- Anagrelide — retroperitoneal hemorrhage
- Apixaban — retroperitoneal hemorrhage
- Aspirin — retroperitoneal hemorrhage
- Celecoxib — retroperitoneal hemorrhage
- Citalopram — retroperitoneal hemorrhage
- Dalteparin sodium — retroperitoneal hemorrhage
- Diclofenac — retroperitoneal hemorrhage
- Fluoxetine — retroperitoneal hemorrhage
- Fluvoxamine — retroperitoneal hemorrhage
- Ibuprofen — retroperitoneal hemorrhage
- Indometacin — retroperitoneal hemorrhage
- Ketoprofen — retroperitoneal hemorrhage
- Meloxicam — retroperitoneal hemorrhage
- Naproxen — retroperitoneal hemorrhage
- Paroxetine — retroperitoneal hemorrhage
- Piroxicam — retroperitoneal hemorrhage
- Rivaroxaban — retroperitoneal hemorrhage
- Sertraline — retroperitoneal hemorrhage
- Streptokinase — retroperitoneal hemorrhage
- Atazanavir
- Carbamazepine
- Clarithromycin
- Digoxin
- Indinavir anhydrous
- Lovastatin
- Morphine
- Nelfinavir
- Phenobarbital
- Phenytoin
Brand names
United States
Brilinta
European Union
Brilique
Canada
Ag-Ticagrelor · Apo-Ticagrelor · Brilinta · Jamp Ticagrelor · M-Ticagrelor · Taro-Ticagrelor · Teva-Ticagrelor
Approval status
- US Food and Drug Administration
- prescription · since 2011
- European Medicines Agency
- authorised · since 2010
- Health Canada
- prescription · marketed
- First approval anywhere
- 2010
Codes
- ATC
- B01AC24
- RxNorm CUI
- 1116632
- ChEMBL
- CHEMBL398435
- PubChem CID
- 9871419
- UNII
- GLH0314RVC
- Wikidata
- Q420542
Frequently asked questions
What is Ticagrelor used for?
Ticagrelor is used for: Acute myocardial infarction, Heart disease, Unstable angina, Acute coronary syndrome, Myocardial infarction, Thrombosis, Stroke, and Coronary artery disease.
What kind of medicine is Ticagrelor?
Ticagrelor is an active ingredient of the class «antithrombotic».
What are the brand names of Ticagrelor?
Brand names of Ticagrelor include Brilinta, Brilique, Ag-Ticagrelor, Apo-Ticagrelor, Jamp Ticagrelor, M-Ticagrelor, Taro-Ticagrelor, and Teva-Ticagrelor.
Medicines in the same class
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)